Benznidazole in cerebrospinal fluid. a case series of chagas disease meningoencephalitis in hiv positive patients.

ConclusionsWe observed BNZ concentrations in human CSF and plasma. CSF BNZ concentrations were low or non-measurable in all patients, suggesting that usual BNZ doses may be suboptimal in HIV positive patients with T. cruzi meningoencephalitis. While drug-drug and drug-disease interactions may be in part responsible, the factors leading to low CSF BNZ levels remain to be studied in detail. The findings highlight the potential of therapeutic drug monitoring in BNZ treatment, and suggest that use of higher doses may be useful for Chagas disease CNS reactivations. PMID: 33361290 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33361290?dopt=Abstract

Source: Antimicrobial Agents and Chemotherapy - December 23, 2020 Category: Microbiology Authors: Fernández ML, Marson ME, Mastrantonio GE, Corti MA, Fleitas U, Lloveras SC, Lista N, Priarone MM, Domínguez C, Garcia-Bournissen F Tags: Antimicrob Agents Chemother Source Type: research